Aflibercept vs Aflibercept (Vgenfli)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
Aflibercept · Eylea
Marketed by Regeneron Pharmaceuticals and partners
NCT00509795 · Phase 3 · completed
The trial randomly assigned 1,217 participants and used quadruple blinding with ranibizumab as an active comparator. Its hard clinical primary endpoint—maintaining vision at week 52—met the prespecified non-inferiority criterion for all three aflibercept regimens, supporting a strong evidence grade.
Next expected readout: June 2027 · NCT04932980 (registry estimate)
Reported efficacy
Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) (Baseline and at week 52): IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 95.1 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 95.9 percentage of patients (spread 0) | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 95.1 percentage of patients (spread 0) vs Ranibizumab 0.5mg Q4 94.4 percentage of patients (spread 0) (met)
Result source: NCT00509795
Aflibercept (Vgenfli)
Marketed by Polpharma S.A. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Age-Related Macular Degeneration
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Aflibercept (Vgenfli): no structured comparison results are available for Age-Related Macular Degeneration.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aflibercept
show 2 more results
show 2 more results
show 2 more results
show 5 more results
show 2 more results
show 7 more results
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 63 further endpoints in the CSV export.
Available safety results
Aflibercept
| Dropout rate | 3.6%2.0mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 44 more results8.9%2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 8.9%0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 10.2%2 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 9.3%2 mg Q8 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 11.9%0.5 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 0%Fixed Group NCT03117634 · Phase 4 · registry result, not featured evidence 4.9%Personalised Group NCT03117634 · Phase 4 · registry result, not featured evidence 7.7% NCT03022292 · Phase 4 · registry result, not featured evidence 6.1% NCT02689518 · Phase 4 · registry result, not featured evidence 11.9%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 14%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 12.9%2 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 15.4%4 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 100%Aflibercept (Non-randomized) NCT02120950 · Phase 4 · registry result, not featured evidence 8.7%Aflibercept + Active PDT NCT02120950 · Phase 4 · registry result, not featured evidence · combination —Aflibercept + Sham PDT NCT02120950 · Phase 4 · registry result, not featured evidence · combination 12.7%Aflibercept + Sham Photodynamic Th NCT02120950 · Phase 4 · registry result, not featured evidence · combination 18.2% NCT01722045 · Phase 4 · registry result, not featured evidence 6.3% NCT01950741 · Phase 4 · registry result, not featured evidence 2.2%2.0 mg NCT01543568 · Phase 4 · registry result, not featured evidence 0%8 mg NCT05989126 · Phase 3 · registry result, not featured evidence 8.3%2 mg every 8 weeks NCT02540954 · Phase 3 · registry result, not featured evidence 11.3%Aflibercept Extended Dosing NCT02540954 · Phase 3 · registry result, not featured evidence —6 mg NCT03386474 · Phase 3 · registry result, not featured evidence 0.9%Brolucizumab - Overall Extension S NCT03386474 · Phase 3 · registry result, not featured evidence —Brolucizumab Overall Last 6 Months NCT03386474 · Phase 3 · registry result, not featured evidence 6.6%Aflibercept Injection (EYLEA, VEGF NCT01482910 · Phase 3 · registry result, not featured evidence —Aflibercept Injection, From Week 2 NCT01482910 · Phase 3 · registry result, not featured evidence —Aflibercept Injection, up to Week NCT01482910 · Phase 3 · registry result, not featured evidence —PDT Then Aflibercept Injection, Fr NCT01482910 · Phase 3 · registry result, not featured evidence · combination 95% NCT00964795 · Phase 3 · registry result, not featured evidence 9.7%RBM-007 + Aflibercept NCT04200248 · Phase 2 · registry result, not featured evidence · combination 9.4%Sham + RBM-007 NCT04200248 · Phase 2 · registry result, not featured evidence · combination 3.8% NCT04126317 · Phase 2 · registry result, not featured evidence 10.3%4.0 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 5%0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 21.1%Monotherapy NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy 23.6%2mg NCT00527423 · Phase 2 · registry result, not featured evidence —2.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —2.0 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —4.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence 22.5% NCT01773954 · Phase na · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | 1%2.0mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 44 more results1.3%2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 1.6%0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 1.9%2 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2.9%2 mg Q8 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2.6%0.5 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 —Fixed Group NCT03117634 · Phase 4 · registry result, not featured evidence —Personalised Group NCT03117634 · Phase 4 · registry result, not featured evidence — NCT03022292 · Phase 4 · registry result, not featured evidence — NCT02689518 · Phase 4 · registry result, not featured evidence 3%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 4.4%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 3.2%2 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 1.6%4 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 20%Aflibercept (Non-randomized) NCT02120950 · Phase 4 · registry result, not featured evidence 2.5%Aflibercept + Active PDT NCT02120950 · Phase 4 · registry result, not featured evidence · combination —Aflibercept + Sham PDT NCT02120950 · Phase 4 · registry result, not featured evidence · combination 3.2%Aflibercept + Sham Photodynamic Th NCT02120950 · Phase 4 · registry result, not featured evidence · combination 5.2% NCT01722045 · Phase 4 · registry result, not featured evidence — NCT01950741 · Phase 4 · registry result, not featured evidence —2.0 mg NCT01543568 · Phase 4 · registry result, not featured evidence —8 mg NCT05989126 · Phase 3 · registry result, not featured evidence 1.2%2 mg every 8 weeks NCT02540954 · Phase 3 · registry result, not featured evidence 2.4%Aflibercept Extended Dosing NCT02540954 · Phase 3 · registry result, not featured evidence —6 mg NCT03386474 · Phase 3 · registry result, not featured evidence 0%Brolucizumab - Overall Extension S NCT03386474 · Phase 3 · registry result, not featured evidence —Brolucizumab Overall Last 6 Months NCT03386474 · Phase 3 · registry result, not featured evidence 2.6%Aflibercept Injection (EYLEA, VEGF NCT01482910 · Phase 3 · registry result, not featured evidence —Aflibercept Injection, From Week 2 NCT01482910 · Phase 3 · registry result, not featured evidence —Aflibercept Injection, up to Week NCT01482910 · Phase 3 · registry result, not featured evidence —PDT Then Aflibercept Injection, Fr NCT01482910 · Phase 3 · registry result, not featured evidence · combination 3.7% NCT00964795 · Phase 3 · registry result, not featured evidence —RBM-007 + Aflibercept NCT04200248 · Phase 2 · registry result, not featured evidence · combination —Sham + RBM-007 NCT04200248 · Phase 2 · registry result, not featured evidence · combination 1.9% NCT04126317 · Phase 2 · registry result, not featured evidence —4.0 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination —0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination —Monotherapy NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy 3.2%2mg NCT00527423 · Phase 2 · registry result, not featured evidence —2.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —2.0 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —4.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence — NCT01773954 · Phase na · registry result, not featured evidence |
| Serious AEs | 23%2.0mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 44 more results29.7%2.0mg Q8 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 28.9%0.5mg Q4 NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 26.2%2 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 26.4%2 mg Q8 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 24.2%0.5 mg Q4 NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 0%Fixed Group NCT03117634 · Phase 4 · registry result, not featured evidence 7.7%Personalised Group NCT03117634 · Phase 4 · registry result, not featured evidence 3.8% NCT03022292 · Phase 4 · registry result, not featured evidence — NCT02689518 · Phase 4 · registry result, not featured evidence 21.5%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 25.7%2 mg intravitreal NCT02581891 · Phase 4 · registry result, not featured evidence 15.3%2 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 16.3%4 Weeks Adjustment NCT02305238 · Phase 4 · registry result, not featured evidence 26.7%Aflibercept (Non-randomized) NCT02120950 · Phase 4 · registry result, not featured evidence 15.5%Aflibercept + Active PDT NCT02120950 · Phase 4 · registry result, not featured evidence · combination 17.2%Aflibercept + Sham PDT NCT02120950 · Phase 4 · registry result, not featured evidence · combination —Aflibercept + Sham Photodynamic Th NCT02120950 · Phase 4 · registry result, not featured evidence · combination 29.2% NCT01722045 · Phase 4 · registry result, not featured evidence 2.1% NCT01950741 · Phase 4 · registry result, not featured evidence 20%2.0 mg NCT01543568 · Phase 4 · registry result, not featured evidence 5.7%8 mg NCT05989126 · Phase 3 · registry result, not featured evidence 13.7%2 mg every 8 weeks NCT02540954 · Phase 3 · registry result, not featured evidence 15.6%Aflibercept Extended Dosing NCT02540954 · Phase 3 · registry result, not featured evidence 6.5%6 mg NCT03386474 · Phase 3 · registry result, not featured evidence —Brolucizumab - Overall Extension S NCT03386474 · Phase 3 · registry result, not featured evidence 6.5%Brolucizumab Overall Last 6 Months NCT03386474 · Phase 3 · registry result, not featured evidence —Aflibercept Injection (EYLEA, VEGF NCT01482910 · Phase 3 · registry result, not featured evidence 2.3%Aflibercept Injection, From Week 2 NCT01482910 · Phase 3 · registry result, not featured evidence 5.7%Aflibercept Injection, up to Week NCT01482910 · Phase 3 · registry result, not featured evidence 4.2%PDT Then Aflibercept Injection, Fr NCT01482910 · Phase 3 · registry result, not featured evidence · combination 32.5% NCT00964795 · Phase 3 · registry result, not featured evidence 6.9%RBM-007 + Aflibercept NCT04200248 · Phase 2 · registry result, not featured evidence · combination 7.1%Sham + RBM-007 NCT04200248 · Phase 2 · registry result, not featured evidence · combination 13.2% NCT04126317 · Phase 2 · registry result, not featured evidence 10.3%4.0 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 10%0.5 mg iSONEP NCT01414153 · Phase 2 · registry result, not featured evidence · combination 15.8%Monotherapy NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy 45.9%2mg NCT00527423 · Phase 2 · registry result, not featured evidence —2.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —2.0 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence —0.5 mg q4 NCT00320788 · Phase 2 · registry result, not featured evidence —4.0 mg q12 NCT00320788 · Phase 2 · registry result, not featured evidence 5% NCT01773954 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | 2.0mg Q4 vitreous floaters 16.1% nasopharyngitis 15.1% eye disorders pain 12.8% NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 show 39 more results2.0mg Q8 nasopharyngitis 12.9% hypertension 10.9% eye disorders pain 10.2% NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 0.5mg Q4 nasopharyngitis 13.5% retinal haemorrhage 11.8% eye disorders pain 11.5% NCT00509795 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2 mg Q4 retinal haemorrhage 27.2% visual acuity reduced 14.2% hypertension 13.3% NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 2 mg Q8 retinal haemorrhage 26.7% visual acuity reduced 19.5% macular degeneration 16.6% NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 0.5 mg Q4 retinal haemorrhage 23.6% visual acuity reduced 18.5% conjunctival haemorrhage 15.5% NCT00637377 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 drop in visual acuity 7.7% punctate epithelial erosion 7.7% raised blood pressure 7.7% NCT03117634 · Phase 4 · registry result, not featured evidence drop in vision due to cataract 5.1% drop in visual acuity 5.1% peri-orbital oedema (extra-ocular) 2.6% NCT03117634 · Phase 4 · registry result, not featured evidence myelodysplastic syndrome 3.8% pneumonia 3.8% NCT03022292 · Phase 4 · registry result, not featured evidence 2 mg intravitreal visual acuity reduced 15.6% conjunctival haemorrhage 14.8% nasopharyngitis 13.3% NCT02581891 · Phase 4 · registry result, not featured evidence 2 mg intravitreal conjunctival haemorrhage 13.2% nasopharyngitis 12.5% visual acuity reduced 12.5% NCT02581891 · Phase 4 · registry result, not featured evidence nasopharyngitis 21% cataract 4% conjunctival haemorrhage 3.2% NCT02305238 · Phase 4 · registry result, not featured evidence nasopharyngitis 16.3% cataract 8.1% conjunctival haemorrhage 6.5% NCT02305238 · Phase 4 · registry result, not featured evidence hypertension 13.3% depression 6.7% ocular hypertension 6.7% NCT02120950 · Phase 4 · registry result, not featured evidence viral upper respiratory tract infection 11.2% hypertension 8.1% dry eye 6.8% NCT02120950 · Phase 4 · registry result, not featured evidence · combination viral upper respiratory tract infection 15.9% conjunctival haemorrhage 6.4% vitreous floaters 5.7% NCT02120950 · Phase 4 · registry result, not featured evidence · combination neovascular age-related macular degeneration 13% hypertension 8.4% conjunctival haemorrhage 7.8% NCT01722045 · Phase 4 · registry result, not featured evidence conjunctival hemorrhage 8.5% NCT01950741 · Phase 4 · registry result, not featured evidence 2.0 mg cataract progression 6.7% geographic atrophy progression 6.7% NCT01543568 · Phase 4 · registry result, not featured evidence 2 mg every 8 weeks cataract 11.3% subretinal fluid 8.3% nasopharyngitis 7.1% NCT02540954 · Phase 3 · registry result, not featured evidence cataract 10.2% subretinal fluid 8.4% visual acuity reduced 8.4% NCT02540954 · Phase 3 · registry result, not featured evidence 6 mg nasopharyngitis 4.7% urinary tract infection 3.7% neovascular age-related macular degeneration - fellow eye 1.9% NCT03386474 · Phase 3 · registry result, not featured evidence urinary tract infection 5.6% nasopharyngitis 3.7% neovascular age-related macular degeneration - fellow eye 1.9% NCT03386474 · Phase 3 · registry result, not featured evidence conjunctival haemorrhage 6% macular fibrosis 2.8% retinal pigment epitheliopathy 2.8% NCT01482910 · Phase 3 · registry result, not featured evidence macular fibrosis 11.8% visual acuity reduced 7% conjunctival haemorrhage 6.1% NCT01482910 · Phase 3 · registry result, not featured evidence visual acuity reduced 7% conjunctival haemorrhage 5.6% intraocular pressure increased 1.4% NCT01482910 · Phase 3 · registry result, not featured evidence · combination retinal haemorrhage 12.1% retinal haemorrhage 10.5% age-related macular degeneration 9.3% NCT00964795 · Phase 3 · registry result, not featured evidence eye disorders 51.7% conjunctival haemorrhage 20.7% eye irritation 6.9% NCT04200248 · Phase 2 · registry result, not featured evidence · combination eye disorders 46.4% conjunctival haemorrhage 17.9% dry eye 14.3% NCT04200248 · Phase 2 · registry result, not featured evidence · combination neovascular age-related macular degeneration fellow eye 7.5% vitreous detachment study eye 7.5% conjunctival haemorrhage fellow eye 5.7% NCT04126317 · Phase 2 · registry result, not featured evidence 4.0 mg iSONEP conjunctival haemorrhage 53.8% intraocular pressure increased 28.2% vitreous floaters 20.5% NCT01414153 · Phase 2 · registry result, not featured evidence · combination 0.5 mg iSONEP conjunctival haemorrhage 60% activated partial thromboplastin time prolonged 12.5% vitreous floaters 12.5% NCT01414153 · Phase 2 · registry result, not featured evidence · combination conjunctival haemorrhage 34.2% retinal haemorrhage 28.9% arthralgia 7.9% NCT01414153 · Phase 2 · registry result, not featured evidence · monotherapy 2mg fall 18.5% hypertension 16.6% nasopharyngitis 16.6% NCT00527423 · Phase 2 · registry result, not featured evidence 2.0 mg q12 upper respiratory tract infection 19.4% blepharitis 9.7% retinal haemorrhage 9.7% NCT00320788 · Phase 2 · registry result, not featured evidence 2.0 mg q4 urinary tract infection 19.4% eye pain 12.9% visual acuity reduced 12.9% NCT00320788 · Phase 2 · registry result, not featured evidence 0.5 mg q12 refraction disorder 12.5% headache 9.4% intraocular pressure increased 9.4% NCT00320788 · Phase 2 · registry result, not featured evidence 0.5 mg q4 hypertension 18.8% bronchitis 15.6% constipation 15.6% NCT00320788 · Phase 2 · registry result, not featured evidence 4.0 mg q12 vitreous detachment 12.9% bronchitis 9.7% eye pain 9.7% NCT00320788 · Phase 2 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aflibercept's landscape · Aflibercept (Vgenfli)'s landscape